Contributions
Abstract: PB1864
Type: Publication Only
Background
The lymphomas are a heterogeneous group of malignant diseases. The exact diagnosis, precise staging and follow up is very important for treatment and prognosis of these patients (pts). Accurate pretreatment evaluation and response assessment are critical to the optimal management of lymphoma pts. Differentiation of post-therapeutic residual tissue from active lymphoma is unsatisfactory when using only morphological imaging approaches. Positron emission tomography/computed tomography (PET/CT) is the most sensitive and specific imaging technique for monitoring therapy response currently available for lymphoma pts after standard chemotherapy and determining which pts would benefit from additional treatment.
Aims
The aim of the study was to assess the clinical value of 18F-FDG PET/CT for staging and response evaluation in lymphoma pts with Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL).
Methods
Results
By applying PET/CT results two pts’ groups were formed: 1.group (n=153 pts) with negative PET/CT results (Deauville score 1-3) and 2.group (n=73 pts) with PET/CT positive results (partial metabolic response or progressive disease). Using Deauville criteria complete response was observed in 95 patients (70.9%) NHL and 58 (63%) HD pts. These pts were in continuous complete remission. Partial response, stable or progressive disease (Deauville score 4-5) were detected in 39 (29.1%) and 34 (37%) NHL and HD pts, respectively. One hypermetabolic lesions and disseminated nodal or extranodal involvement were detected in 15 and 24 NHL pts as well in 12 and 22 HD pts. The pts with one hypermetabolic lesions were considered for radiotherapy, while pts with more than one nodal or extranodal lesions after completion of standard chemotherapy were considered for high dose chemotherapy ± autologous stem cell transplantation (ASCT).
Conclusion
18F-FDG PET was useful in HD and NHL pts after standard chemotherapy not only for determination of those who need additional therapy, but for the choice of the further management: radiotherapy, chemotherapy, or ASCT. A negative PET/CT study after the completion of therapy is an excellent predictor of good prognosis.
Session topic: 17. Hodgkin lymphoma - Clinical
Keyword(s): Non-Hodgkin's lymphoma, Hodgkin's disease, PET
Abstract: PB1864
Type: Publication Only
Background
The lymphomas are a heterogeneous group of malignant diseases. The exact diagnosis, precise staging and follow up is very important for treatment and prognosis of these patients (pts). Accurate pretreatment evaluation and response assessment are critical to the optimal management of lymphoma pts. Differentiation of post-therapeutic residual tissue from active lymphoma is unsatisfactory when using only morphological imaging approaches. Positron emission tomography/computed tomography (PET/CT) is the most sensitive and specific imaging technique for monitoring therapy response currently available for lymphoma pts after standard chemotherapy and determining which pts would benefit from additional treatment.
Aims
The aim of the study was to assess the clinical value of 18F-FDG PET/CT for staging and response evaluation in lymphoma pts with Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL).
Methods
Results
By applying PET/CT results two pts’ groups were formed: 1.group (n=153 pts) with negative PET/CT results (Deauville score 1-3) and 2.group (n=73 pts) with PET/CT positive results (partial metabolic response or progressive disease). Using Deauville criteria complete response was observed in 95 patients (70.9%) NHL and 58 (63%) HD pts. These pts were in continuous complete remission. Partial response, stable or progressive disease (Deauville score 4-5) were detected in 39 (29.1%) and 34 (37%) NHL and HD pts, respectively. One hypermetabolic lesions and disseminated nodal or extranodal involvement were detected in 15 and 24 NHL pts as well in 12 and 22 HD pts. The pts with one hypermetabolic lesions were considered for radiotherapy, while pts with more than one nodal or extranodal lesions after completion of standard chemotherapy were considered for high dose chemotherapy ± autologous stem cell transplantation (ASCT).
Conclusion
18F-FDG PET was useful in HD and NHL pts after standard chemotherapy not only for determination of those who need additional therapy, but for the choice of the further management: radiotherapy, chemotherapy, or ASCT. A negative PET/CT study after the completion of therapy is an excellent predictor of good prognosis.
Session topic: 17. Hodgkin lymphoma - Clinical
Keyword(s): Non-Hodgkin's lymphoma, Hodgkin's disease, PET